Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

• Status: Withdrawn
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institute of Liver and Biliary Sciences, India
• Treatments: Adrenergic beta-Antagonists; Carvedilol

Criteria

Inclusion Criteria:

• Patients of cirrhosis with Hepatocellular carcinoma and portal vein thrombosis

• Presence of large oesophageal varices or small with high risk

Exclusion Criteria:

• Any contra-indication to beta-blockers

• Any Endoscopic Variceal Ligation or Sclerotherapy within last 3 months

• High risk gastric varices

• Any past history of Transhepatic Intrajugular Portosystemic Shunt or surgery for portal hypertension

• Significant cardio or pulmonary co-morbidity

• Any extrahepatic malignancy

• Patients with past history of variceal bleed

• Patients with non-tumor portal vein thrombosis

• Refusal to participate in the study